Recombinant Human Neuropilin-1 (C-mFc)

Description

EnkiLife provides the Recombinant Human Neuropilin-1 (C-mFc) protein,aslo know as CD304,NRP1,NRPNP1,VEGF165R,BDCA4, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Neuropilin-1 is produced by our Mammalian expression system and the target gene encoding Phe22-Lys644 is expressed with a mouse IgG1 Fc tag at the C-terminus.Accession:AAH07533.1. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:96.2 KDa. Background:Neuropilin-1 (Npn-1, previously neuropilin; also CD304) is a 130 - 140 kDa type I transmembrane (TM) glycoprotein that regulates axon guidance and angiogenesis. Two homologues, Neuropilin-1 and Neuropilin-2, are identified. Neuropilin-1 binds to semaphorin 3A, The PLGF-2 isoform of PGF, The VEGF-165 isoform of VEGF and VEGF-B. Coexpression with KDR results in increased VEGF-165 binding to KDR as well as increased chemotaxis. It may regulate VEGF-induced angiogenesis. The soluble isoform 2 binds VEGF-165 and appears to inhibit its binding to cells. NRP1 expression is regulated in EC by tumor necrosis factor-alpha, the transcription factors dHAND and Ets-1, and vascular injury. NRP1 upregulation is positively correlated with the progression of various tumors.